Bendamustine 180mg/4ml solution for infusion vials
Requires a prescription from a doctor or prescriber
Bendamustine is a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL).
Safety information for pregnancy and breastfeeding
Pregnancy
Always consult your doctor or midwife before taking any medicine during pregnancy or while breastfeeding. Source: DrugBank (CC BY-NC 4.0).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Bendamustine
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Bendamustine
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Bendamustine
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Bendamustine on the MHRA register
Bendamustine 180mg/4ml concentrate for solution for infusion vials
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(12)
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)
Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649)
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal) (TA206)
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) (TA437)
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma (TA883)
Mosunetuzumab for treating relapsed or refractory follicular lymphoma (TA892)
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)
Obinutuzumab for untreated advanced follicular lymphoma (TA513)
Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 4 · Randomised trials: 19 · 2005–2026
Showing the 50 most relevant studies, sorted by most relevant.
Paolo Ghia, Andrzej Pluta, Małgorzata Wach, et al.
Journal of Clinical Oncology, 2020
- Rituximab
- Bendamustine Hydrochloride
- Progression-Free Survival
Constantine S. Tam, Jennifer R. Brown, Brad S. Kahl, et al.
The Lancet Oncology, 2022
- COVID-19
- Leukemia, Lymphocytic, Chronic, B-Cell
- Sequoia
Barbara Eichhorst, Anna‐Maria Fink, Jasmin Bahlo, et al.
The Lancet Oncology, 2016
- Immunotherapy
- Rituximab
- Bendamustine Hydrochloride
Laurie H. Sehn, Neil Chua, Jiřı́ Mayer, et al.
The Lancet Oncology, 2016
- Rituximab
- Bendamustine Hydrochloride
- Antineoplastic Combined Chemotherapy Protocols
Andrew D. Zelenetz, Jacqueline C. Barrientos, Jennifer R Brown, et al.
The Lancet Oncology, 2017
- Rituximab
- Bendamustine Hydrochloride
- Antineoplastic Combined Chemotherapy Protocols
Mathias Rummel, N. Niederle, Georg Maschmeyer, et al.
The Lancet, 2013
- Rituximab
- Bendamustine Hydrochloride
- Antineoplastic Combined Chemotherapy Protocols
Ian W. Flinn, Richard van der Jagt, Brad S. Kahl, et al.
Blood, 2014
- Rituximab
- Bendamustine Hydrochloride
- Alopecia
Mathias Rummel, Ulrich Kaiser, Christina Balser, et al.
The Lancet Oncology, 2015
- Rituximab
- Bendamustine Hydrochloride
- Antineoplastic Combined Chemotherapy Protocols
Miyashita A, Castellanos MSJ, Rodgers T
2026
- Hematologic Neoplasms
- Vidarabine
- Antineoplastic Combined Chemotherapy Protocols
Mohammed Saleh MF, Abdrabou A, Alnughmush A, et al.
2026
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
40 minutes
Mechanism
Bendamustine is a bifunctional mechlorethamine derivative capable of forming ele…
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
40 minutes
Protein binding
94-96%
Volume of distribution
20-25 L
Metabolism
10th
Elimination
76%
Clearance
700 mL/min
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L50632]
The indication for chronic lymphocytic leukemia (CLL) was removed from the US drug label in April 2024.
[L50632]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 953 interactions
Discontinue use in the event of severe/progressive skin reactions.
Hematologic malignancies of different forms reported.
Discontinue use in the case of severe infusion reactions.
May cause extravasation.
Mild to moderate renal impairment.
Mild hepatic impairment.
Sepsis (infections) may occur.
Avoid use if pregnant.
Possibility of anaphylaxis or infusion reactions- severe in rare cases.
How the body processes this drug — absorption, distribution, metabolism, and elimination
Results of a human mass balance study confirm that bendamustine is extensively metabolized via hydrolytic, oxidative, and conjugative pathways.
Less than 1% of the dose was recovered in the urine as M3 and M4, and less than 5% of the dose was recovered in the urine as HP2.
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC L01AA09
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Bendamustine
Additional database identifiers
Drugs Product Database (DPD)
13270
ChemSpider
59069
BindingDB
173621
ZINC
ZINC000004214955
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2596
GenAtlas
CYP1A2
GeneCards
CYP1A2
GenBank Gene Database
Z00036
Guide to Pharmacology
1319
UniProt Accession
CP1A2_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72